Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Patricia S. Fox||en_US|
|dc.contributor.author||Stephen G. Swisher||en_US|
|dc.contributor.author||Eric M. Rohren||en_US|
|dc.contributor.author||Roland L. Bassett||en_US|
|dc.contributor.author||Homer A. Macapinlac||en_US|
|dc.contributor.other||University of Texas MD Anderson Cancer Center||en_US|
|dc.identifier.citation||European Journal of Nuclear Medicine and Molecular Imaging. Vol.41, No.5 (2014), 906-914||en_US|
|dc.description.abstract||Purpose: Our objective was to determine the impact of initial18F-FDG PET/CT (PET/CT) staging on clinical stage and the management plan and the prognostic value of PET/CT in patients with non-small-cell lung cancer (NSCLC). Methods: We retrospectively reviewed the records of 592 patients with NSCLC who were referred to The University of Texas MD Anderson Cancer Center during 2002/2011 and had both PET/CT and conventional CT for initial staging. Clinical stages and management plans were compared between PET/CT and CT. The impact of PET/CT on management plans was considered medium/high when PET/CT changed the planned treatment modality or treatment intent. PET/CT and CT stages were compared with all-cause mortality and survival rates. We also assessed potential prognostic factors for progression-free survival (PFS) and overall survival (OS). Results: PET/CT changed the stage in 170 patients (28.7 %; 16.4 % upstaged, 12.3 % downstaged). PET/CT had a medium/high impact on the management plan in 220 patients (37.2 %). PFS and OS were significantly worse in patients with upstaged disease than in patients with no change in stage (median PFS 29.0 vs. 53.8 months, P<0.001; median OS:64.7 vs. 115.9 months, P=0.006). PFS and OS were significantly worse in patients with medium/high impact of PET/CT than in patients with no/low impact of PET/CT (median PFS 24.7 vs. 60.6 months, P<0.001; median OS 64.7 vs. 115.9 months, P<0.001). In multivariate analysis, a medium/high impact of PET/CT was an independent predictor of worse PFS (hazard ratio, HR, 1.73; 95 % CI 1.30 - 2.29; P=0.0002) and OS (HR 1.84; 95 % CI 1.26 - 2.69; P=0.002). Conclusion: Initial PET/CT staging not only impacts stage and management plan but also has prognostic value. © 2014 Springer-Verlag Berlin Heidelberg.||en_US|
|dc.title||Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer||en_US|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.